Pliant Therapeutics, Inc. is a medium-risk Pharmaceuticals company in the United States specializing in the development of novel therapies for fibrosis and related diseases. The company's primary focus is on bexotegrast (PLN-74809), an oral, small molecule treatment targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. With an ESG score of 25.3, Pliant Therapeutics is committed to sustainability and governance practices in the pharmaceutical industry.